PLCG2 and CALM1 of Ca2+-calmodulin signalling pathways are the two potential targets for gene knockdown in doxorubicin and paclitaxel-based chemotherapy of cervical cancer. This evidence concerns the gene CALM1 and cervical carcinoma.